Navigation Links
VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
Date:11/20/2008

    International Agreement Licenses Seno's Opto-Acoustic Imaging Technology
    To VisualSonics to Enable Molecular Imaging at the Cellular Level and Aid
    in the Pursuit of Neurology, Regenerative Medicine, Inflammation, and
    Cancer Applications

TORONTO and SAN ANTONIO, TX, Nov. 20 /PRNewswire/ - VisualSonics and Seno Medical Instruments today announced the official signing of a licensing agreement providing VisualSonics exclusive rights to Seno Medical's Opto-Acoustic technology for preclinical research.

"The application of opto-acoustic technology to our Vevo(R) preclinical imaging platform is an exciting new area for VisualSonics" stated Tom Little, President and Chief Executive Officer of VisualSonics, "We will be enabling researchers to push the limits of discovery as we develop tools for intracellular and molecular imaging with VisualSonics technology and Seno Medical IP."

VisualSonics will embed Seno's opto-acoustic technology in their next generation of high-frequency ultrasound platforms and this will extend their molecular imaging capability to the sub cellular level. This combination will drive the new molecular imaging utility for the next generation of preclinical imaging with the Vevo platform.

"Seno's preclinical opto-acoustic platform technology will enable researchers to non-invasively detect and monitor biological structures, functions and processes at the cellular and molecular level as well as potentially provide the ability to monitor and quantify hypoxia (oxygenated vs. deoxygenated tissue or cells), and to reveal information on tumor development, disease progression and inflammation processes that were previously unattainable," said Janet Campbell, Chairman and CEO of Seno Medical Instruments. "For this reason, there is great interest in our opto-acoustic technology for both clinical and preclinical applications. We look forward to working with VisualSonics, a market leader, and recognize that this licensing agreement further validates the value of our platform technology."

VisualSonics, the current market leader in pre-clinical high-frequency micro-ultrasound imaging systems used for small animal research, has licensed Seno Medical Instrument's opto-acoustic imaging technology to enable researchers to non-invasively detect and monitor biological structures, functions and processes at the cellular and molecular level. Since 2003, VisualSonics has sold more than 500 of its Vevo(R) imaging systems and researchers are using them widely to generate anatomical and functional data in research areas that include angiogenesis, tumor growth, and cardiovascular disease in small animal models. The Vevo platforms current imaging capabilities assist scientists to better understand phenotypes, structure and function and to better understand how genes affect diseases and responses to treatments. Micro-ultrasound imaging provides a noninvasive tool for viewing complex biological mechanisms in real-time.

About Seno Medical Instruments, Inc.

Seno Medical Instruments, Inc. is a San Antonio based medical device developer focused on the early detection of cancer thru the use of its patented opto-acoustic technology. Opto-acoustic imaging combines light and sound to produce high-resolution, high-contrast images to indicate the presence of increased blood supply and vascular structure that surround and feed a tumor. To learn more about Seno Medical's opto-acoustic imaging technology and applications, visit www.SenoMedical.com

About VisualSonics

VisualSonics is the world's leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company's enabling technology allows researchers at the world's most prestigious pharma/biotech companies, hospitals and universities to conduct research into cardiovascular disease, cancer, and developmental biology including genetic research, phenotypic study and drug development. Only VisualSonics platforms combine high-resolution, real-time in vivo imaging with ease-of-use, portability and no negative biological effects. More information can be found at www.visualsonics.com.


'/>"/>
SOURCE VisualSonics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
5. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
6. BioMS Medical announces its intention to renew a normal course issuer bid
7. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Globus Medical Announces Record 2nd Quarter 2007 Results
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
(Date:3/22/2017)... 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), ... technology to address significant unmet medical needs in ... full year ended December 31, 2016. ... company as we broadened our pipeline and pursued ... disease company with an initial focus on endocrinology," ...
Breaking Biology Technology:
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
Breaking Biology News(10 mins):